Merck (MRK), known as MSD outside the United States and Canada, has earned a heavyweight spot in the pharmaceutical industry. Its blockbuster cancer immunotherapy Keytruda brought in $31.7 billion in 2025, giving the company a powerful revenue engine alongside its broader portfolio of oncology treatments, vaccines, and cardiometabolic medicines.
Now, the pharmaceutical giant faces another major test as it prepares to report its Q3 FY2026 financial results before the market opens on Thursday, Oct. 29. The results would show whether Keytruda can continue doing the heavy lifting, particularly as Merck expands its subcutaneous formulation, Keytruda Qlex, which delivers the treatment through an injection under the skin.